Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

Tumor Cells ◽

Complete Response ◽

Pooled Analysis ◽

Phase Ii Trials ◽

Multicentre Phase

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Annals of Oncology ◽

10.1093/annonc/mdw535 ◽

2017 ◽

Vol 28 (1) ◽

pp. 103-109 ◽

Cited By ~ 25

Author(s):

J.-Y. Pierga ◽

F.-C. Bidard ◽

A. Autret ◽

T. Petit ◽

F. Andre ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Complete Response ◽

Pooled Analysis ◽

Circulating Tumour Cells ◽

Phase Ii Trials ◽

Multicentre Phase

P1-14-02: Correlation of Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) with Pathological Complete Response (pCR) during Neoadjuvant Chemotherapy (CT) Combined with Bevacizumab in HER2 Negative Inflammatory Breast Cancer (IBC): Ancillary Study of Phase II Trial BEVERLY 1.

10.1158/0008-5472.sabcs11-p1-14-02 ◽

2011 ◽

Author(s):

J-Y Pierga ◽

F-C Bidard ◽

F Andre ◽

T Petit ◽

F Dalenc ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Tumor Cells ◽

Phase Ii Trial ◽

Complete Response ◽

Circulating Endothelial Cells ◽

Ancillary Study

Abstract 381: Circulating tumor cells (CTC) but not circulating endothelial cells (CEC) are independent prognostic factors in neoadjuvant chemotherapy combined with bevacizumab in HER2 negative inflammatory breast cancer (IBC) in multicentre phase II trial BEVERLY1

10.1158/1538-7445.am2015-381 ◽

2015 ◽

Author(s):

Jean-Yves Pierga ◽

Francois-Clement Bidard ◽

Aurelie Autret ◽

Fabrice Andre ◽

Thierry Petit ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Prognostic Factors ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii Trial ◽

Circulating Endothelial Cells ◽

Multicentre Phase

Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: The importance of Ki-67 and molecular subtype

Annals of Oncology ◽

10.1093/annonc/mdy270.230 ◽

2018 ◽

Vol 29 ◽

pp. viii75

Author(s):

B.L. Rapoport ◽

J.A. Barnard-Tidy ◽

T. Smit ◽

S.J. Nayler ◽

C.A. Benn

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Cancer Patients ◽

Molecular Subtype ◽

Complete Response ◽

Breast Cancer Patients ◽

Ki 67 ◽

Factors Associated

Abstract OT1-02-05: A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy

10.1158/1538-7445.sabcs17-ot1-02-05 ◽

2018 ◽

Author(s):

A Alexander ◽

J Willey ◽

H Sun ◽

CA Parker ◽

AN Marx ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Hormone Receptor ◽

Phase Ii Study ◽

Complete Response

Abstract P1-15-25: Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype

10.1158/1538-7445.sabcs18-p1-15-25 ◽

2019 ◽

Author(s):

BL Rapoport ◽

J Barnard-Tide ◽

T Smit ◽

S Nayler ◽

C-A Benn

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Cancer Patients ◽

Molecular Subtype ◽

Complete Response ◽

Breast Cancer Patients ◽

Ki 67 ◽

Factors Associated

Pathological complete response (pCR) is not a good marker for inflammatory breast cancer (IBC) patients to predict improved long-term survival after neoadjuvant chemotherapy (NT)

Annals of Oncology ◽

10.1093/annonc/mdv117.13 ◽

2015 ◽

Vol 26 ◽

pp. iii15

Author(s):

F. Fei ◽

L. Tang ◽

G. Di

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Term Survival ◽

Long Term Survival ◽

Good Marker

9O_PR Gene Modules and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. A Pooled Analysis

Annals of Oncology ◽

10.1016/s0923-7534(19)65672-3 ◽

2012 ◽

Vol 23 ◽

pp. ii17 ◽

Cited By ~ 1

Author(s):

M. Ignatiadis ◽

S.K. Singhal ◽

C. Desmedt ◽

B. Haibe-Kains ◽

C. Criscitiello ◽

...

Keyword(s):

Breast Cancer ◽

Response To Neoadjuvant Chemotherapy

Complete Response ◽

Pooled Analysis ◽

Gene Modules ◽

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Breast Cancer Research and Treatment ◽

10.1007/s10549-011-1660-6 ◽

2011 ◽

Vol 132 (3) ◽

pp. 843-851 ◽

Cited By ~ 24

Author(s):

Milvia Zambetti ◽

Mauro Mansutti ◽

Patricia Gomez ◽

Ana Lluch ◽

Christian Dittrich ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Complete Response ◽

Operable Breast Cancer ◽

Phase Ii Trials ◽

Randomized Phase Ii ◽

Adaptive Study Design ◽

Er Status

Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer

Magnetic Resonance Materials in Physics Biology and Medicine ◽

10.1007/s10334-021-00941-0 ◽

2021 ◽

Author(s):

Angeline Nemeth ◽

Pierre Chaudet ◽

Benjamin Leporq ◽

Pierre-Etienne Heudel ◽

Fanny Barabas ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Response To Neoadjuvant Chemotherapy

Complete Response ◽